Acute promyelocytic leukemia (APL) patients treated with allremission (CR) rate of as high as 95% in APL patients whose trans retinoic acid (ATRA) and chemotherapy have been shown t(15;17) was documented by molecular or cytogenetic stud- Retinoic acid (RA) syndrome is a life-threatening side-effect of value lower than that of Latino patients but higher than that of
15% of total de novo acute myeloid leukemia (AML). The diagnosis was confirmed in all cases by the presence of t(15;17) in conventional cytogenetic study and/or PML-RAR␣ Introduction fusion transcript in reverse transcriptase polymerase chain reaction (RT-PCR) analysis. Acute promyelocytic leukemia (APL) is a specific subtype of Oral ATRA of 45 mg/m 2 /day was prescribed to all 25 cases acute myeloid leukemia (AML) characterized by the unique who were treated at our institute. It was used for 30-90 days morphology of leukemic cells and by the specific chromodepending on the clinical response. Complete blood cell somal translocation t(15;17) which results in a novel fusion counts, white cell classification, profiles of coagulopathy, biotranscript PML-RAR␣ (retinoic acid receptor ␣ chain). Three chemistry, electrolytes, and side-effects of ATRA were forms of PML-RAR␣ fusion transcript, long (L), short (S), and recorded. RA syndrome was defined as the presence of unexvariant (V) forms, had been detected by molecular studies, plained fever, respiratory distress, pleuropericardial effusion, corresponding to the breakpoints of PML gene in intron 6, pulmonary infiltrate, and weight gain after the start of ATRA. 16 intron 3 and exon 6, respectively. 1 The proportion of these No concurrent full-dose chemotherapy was used even in three forms of fusion transcript varied in different geographic patients who presented with or developed leukocytosis during areas. [2] [3] [4] [5] [6] Coexpression of T cell-associated antigen CD2 on ATRA treatment. When RA syndrome occurred, intravenous the leukemic cells was detected in some APL patients and was dexamethasone 10 mg was administered intravenously for 3-found to be closely related to S form transcript in some 5 days twice a day without discontinuing ATRA. Three reports, 7, 8 but not in others. 9 patients (cases 6,12 and 21) received leukapheresis or lowAll-trans retinoic acid (ATRA) could induce a complete dose hydroxyurea when RA syndrome occurred; all of them presented with high initial and peak peripheral white blood cell (WBC) count. CR was defined as normal marrow cellu- Detection of PML-RAR␣ fusion transcript Cytogenetic study Total RNA was extracted from cryopreserved BM cells by a modified one-step guanidinium-thiocyanate-phenolchloroThe leukemic cells were harvested after 1-3 days in culture medium without stimulants, as described previously.
18 Chroform method using RNAzol B commercial reagent (Biotecx Lab, Houston, Texas, USA). 22 PML-RAR␣ fusion transcript was mosomes were banded by a conventional trypsin-Giemsa technique and karyotyped according to the International Sysdetected by nested PCR following reverse transcription. Briefly, 50 ng of random hexamers were added to 1 g of total tem for Human Cytogenetic Nomenclature.
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RNA in 11 l DEPC-treated water. After heating at 95°C for 5 min followed by cooling in ice bath for 3 min and centrifugation, it was added to a mixture of RNasin 1 l (20 U/l, ProImmunophenotypic study mega, Madison, WI, USA), 0.1 M DTT 1 l, 10 mM dNTP 1 l, 5× reverse transcriptase buffer 4 l, Maloney murine leukemia A panel of monoclonal antibodies (MoAb) to myeloidassociated antigens including CD13, CD14, CD15, CD11b virus reverse transcriptase (200 U/l) 1 l, and H 2 O 1 l to a total volume of 20 l, and then briefly centrifuged and incuand CD41a, to lymphoid-associated antigens including CD19, CD10, CD20, CD2, CD5 and CD7 and to lineage-nonspecific bated for 2 h at 37°C. cDNA synthesized from RT reaction was diluted to 40 l and 5 l was used as a template for PCR, antigens. HLA-DR and CD34 were used to identify the immunophenotypes of the leukemic cells. Indirect immunoalkaline which was run in a volume of 50 l containing 5 l of 1.25 mM dNTP, 50 pmol of each primer and 0.25 l of super phosphatase method was used to show the expression of the surface antigens on the leukemic cells. 20 Leukemic cells isoTaq (5 U/l, HT Biotechnology, Cambridge, UK). The mixture was incubated at 94°C for 1 min, 60°C for 1 min, and 72°C lated from BM or PB by Ficoll-Hypaque gradient centrifugation were incubated with 5% pooled human AB serum and for 45 s with a total of 25 cycles using the Perkin-Elmer-Cetus DNA Thermal Cycler (Norwalk, CT, USA). 23 Nested PCR using then 5% normal goat serum to block nonspecific antibody binding. MoAb and alkaline-phosphate-conjugated goat antianother set of primers were performed with the same procedure as the first round. The PCR product was then elecmouse Ig (Zymed Laboratories, San Francisco, CA, USA) were sequentially incubated with the leukemic cells. Antibody trophoresed on agarose gel and visualized with ethidium bromide under UV lamp. binding was shown by enzyme alkaline phosphatase reaction. Nonimmune normal mouse ascites was used as a negative
The PCR primers for S form of PML-RAR␣ fusion cDNA were as follows: first round, P1, 5Ј-TACCAGCGCGACTACcontrol. If more than 20% of the leukemic cells were positively stained by the antibody, they were considered positive GAGGAG-3Ј (sense orientation) and R1, 5Ј-CAC-TTCAAAGCACTTCTGCAGTCGG-3Ј (antisense) and second for that antigen.
round, P2, 5Ј-TTCAAGGTGCGCCTGCAGGA-3Ј (sense) and R3, 5Ј-CATGTTCTTCTGGATGCTGC-3Ј (antisense). Those for L form of fusion cDNA were as follows: first round, P2 (sense)
Fluorescence in situ hybridization (FISH) and R1 (antisense) and second round, P3, 5Ј-GTCTCCAATA-CAACGACAGC-3Ј (sense) and R3 (antisense). Amplification The cells were prepared in the same way as that for cytogenetic study and were stored at −70°C in methanol:glacial of normal RAR␣ cDNA as internal control was accomplished by using the following primers: first round, R2, 5Ј-CAGCACacetic acid (3:1) until use. The probe mixture consisted of four overlapping digoxigenin-labeled cosmids that spanned the CAGCTTCCAGTTAG-3Ј (sense) and R1 (antisense) and second round, R2 (sense) and R3 (antisense). Amplification of RAR␣ locus at 17q21 and three overlapping biotin-labeled cosmids that spanned the PML locus at 15q22 (Oncor, Gai-␤-actin cDNA was also used as internal control for some patients. Negative controls including normal RNA and disthersburg, MD, USA). 21 The whole procedures were done according to the manufacturer's instructions. Briefly, the cells tilled water were used in each experiment. To avoid contamination, each RNA sample was aliquoted and analyzed for two stored in fixative were dropped onto slides and air-dried. The slides were treated for 30 min at 37°C with 2 × SSC (1 × SSC: different RT-PCR. The presence of PML-RAR␣ fusion transcript was also con-0.15 mol/l NaCl, 0.015 mol/l trisodium citrate), dehydrated with cold ethanol of 70, 80 and 95% for 2 min each, and firmed for most patients by direct cDNA sequencing using a method described previously with some modification. 23 The then denaturated in 70% formamide and 2 × SSC for 2 min at 70°C. The slides were dehydrated successively in cold 70, 80 PCR-amplified cDNA was gel-purified, then sequenced using the PRISM Dye Terminator Cycle Sequencing Core Kit (Perkin and 95% ethanol for 2 min each and air-dried. Each slide was rewarmed to 37°C and hybridized with 10 l of probes in a Elmer, Norwalk, CT, USA) on the ABI Model 373A DNA Sequencer (Applied Biosystems, Foster City, CA, USA). humidified chamber for 16 h at 37°C. After washing, the specimens were processed with a dual-color chromosome in situ kit (Oncor) which included rhodamine-labeled antidigoxigenin (sheep) and fluorescein-labeled avidin. Finally the Statistics slides were counterstained with 4Ј, 6Ј-diamidino-2Ј-phenylindol (DAPI) and then observed under a fluorescent microscope.
The duration of overall survival or disease-free survival was calculated by Kaplan-Meier method and the difference of Abnormal cells would have one green signal on the normal chromosome 15, one red signal on the normal chromosome these durations between groups were estimated by log-rank test. 24, 25 In normal controls, fusion signals were seen in no more than 2% of interphase cells (range 0-2%), so we set the cut-off level Results for PML-RAR␣ at 5% (mean ± 2 s.d. = 2 ± 2.44%). All 16 cases tested had PML-RAR␣ fusion signals in more than 5%
Clinical and hematologic data of the patients of cells, including the one with variant form of translocation and the two without t(15;17) by conventional cytogenetic Twenty-six of the 30 APL patients had typical hypergranular morphology; the remaining four were microgranular varistudy. Seven cases showed two fusion signals in some interphase cells (Figure 1 ). Among them were 2 with ider(17q) ant.
26,27 There were 18 males and 12 females. Age ranged from 9 to 78 years with a median of 37. The initial white cell (cases 11 and 18) and 1 (case 8) with additional unknown material attached to the short arm of the derivative chromocount ranged from 770/l to 158 000/l, with a median of 5600/l. The basic clinical, laboratory, and molecular data of some 17, der(17)t(15;17)add(17)(p11). The two fusion signals were shown to locate on both long arms of the derivative the 25 patients who were treated at our institute are shown in Table 1 
Immunophenotypic study
Immunophenotypic study was performed on leukemic cells from 27 patients. Panmyeloid marker CD33 was detected in all patients analyzed, CD13 in 85% (23/27) of patients, and CD15 in 79%. HLA-DR expression could be demonstrated in only two patients, CD34 and CD14 in one patient each, and CD11b in none. Only two patients were positive for CD34 even though 10% cut-off value was applied. Four patients coexpressed T cell-associated antigen CD2 on the leukemic cells, but none had positive staining for other lymphoid antigens CD5, CD7, CD10, CD19 or CD20.
PML-RAR␣ fusion transcript and its correlation with CD2 expression
All 29 patients studied by RT-PCR, including the two without t(15;17) cytogenetically, showed PML-RAR␣ fusion transcript in the leukemic cells (Figure 2) . Eighteen of them (62%) had L form, 10 (34%) had S form, and one had V form; most of expression. Combined analysis of the data in this study and those from literature revealed significant correlation between CD2 expression and S form of PML-RAR␣ (Table 2 ). There was no association between the morphology of the leukemic cells and isoforms of PML-RAR␣; two of the four patients with microgranular APL had S isoform of the fusion transcript and the other two, L isoform. There was no correlation between morphology and CD2 expression; two patients with microgranular variant coexpressed CD2 while the other two did not.
Response to treatment and retinoic acid syndrome achieved a CR after ATRA treatment; four patients, including the two with WBC count more than 100 000/l at diagnosis, died of complications (three intracranial hemorrhage, and one Correlation of clinical and biological features with sepsis) within 7 days of therapy. All the responsive cases prognosis achieved CR within 2 months, with bone marrow normalization at a median of 30 days.
Among the 21 patients who obtained a CR, 14 patients Hypertriglyceridemia was the most common side-effect received scheduled post-induction chemotherapy with anthra-(10/25, 40%), followed by RA syndrome (9/25, 36%), and skin cycline-containing regimens; nine patients remained in CR, dryness (9/25, 36%). All nine patients with RA syndrome and the median duration of disease-free survival (DFS) and presented typical pictures including pleuropericardial overall survival were 16 and 33 months, respectively. Of the effusion, and respiratory distress 2-25 days after the start of remaining seven patients who achieved CR, five did not ATRA. Seven of them also had fever more than 38°C. One receive any further chemotherapy and two received only lowpatient, who had normal electrocardiography before ATRA dose cytarabine; six of them relapsed and the median duration treatment, developed complete atrio-ventricular conduction of DFS and overall survival were 6 months and 13 months, block during the attack. In seven patients, RA syndrome respectively. occurred shortly before the peak white cell count was Patients with WBC count more than 10 000/l at presenreached, but in one, it happened when there was obvious diftation, peak WBC count more than 50 000/l, or WBC ferentiation of leukemic cells and in relative leukopenia. With increment rate more than 5000/l/day after ATRA treatment the exception of one case who possibly died of both RA synhad a significantly shorter DFS than those with lower values drome and coexistent Staphylococcus aureus sepsis, all the ( Figure 3 ) (median of DFS duration of 6, 6, and 6 months vs other eight patients were successfully treated by 3-5 days with not yet reached, respectively). The association was even more dexamethasone. Patients with higher initial WBC count, peak significant when only the subgroup of the 14 patients receiv-WBC count or WBC increment rate during RA treatment had ing scheduled anthracycline-containing post-induction a higher chance to develop RA syndrome (P = 0.0648, 0.0464, chemotherapy were analyzed (Figure 4 ). There was no sig-0.0464, respectively, by Wilcoxon rank sum test). The peak nificant correlation between DFS duration and WBC count had very good association with the WBC count immunophenotype, isoform of PML-RAR␣ transcript, or at presentation (Spearman correlation, r = 0.78, P = 0.0001).
occurrence of RA syndrome. Although the presence of Neither isoforms of PML-RAR␣ transcript nor immunophenoadditional chromosomal abnormalities as a whole did not types including CD13 and CD15 expression correlated significantly with the development of RA syndrome. influence the prognosis of APL patients, the presence of containing post-remission chemotherapy (Figures 3 and 4) . ider(17q) may be associated with poor prognosis. All three
We suggest that BM transplantation be performed in the first patients with ider(17q) at diagnosis by cytogenetic and FISH CR for patients with high initial or peak WBC counts to obtain studies died, while none of the patients remaining in CR had better long-term disease-free survival. On the other hand, ider(17q) cytogenetically. More patients are necessary to patients with low initial or peak WBC counts are very likely reach a conclusion. Trisomy 8 seemed to have no prognosto be cured by induction treatment with ATRA followed by tic implications.
intensive chemotherapy. The location of the PML breakpoint has been reported to influence prognosis. Patients who expressed S isoform of Discussion PML-RAR␣, with the PML breakpoints in intron 3, had significantly shorter CR duration than did L isoform cases who The patients in this study had higher WBC counts at diagnosis had the breakpoints in intron 6. 5,37 V isoform, with fusion sites (median 5600/l) than those from other institutions (less than in PML gene exon 6, occurred less frequently than the two 2000/l). 11, 17, 28 In 11 of the 25 patients, the value was more common forms. Patients with this rare isoform had decreased than 10 000/l (Table 1 ) and in two, more than 100 000/l.
ATRA sensitivity in vitro and likely a poor prognosis. 42 In this This might reflect different biological behavior of the leukemic report, no significant correlation between the fusion isoform cells from the patients in this study when compared with that and DFS duration or overall survival could be recognized. in others. Forty-two percent (11/26) of the newly diagnosed Although additional chromosomal abnormalities as a whole patients in this study had chromosomal abnormalities in did not influence the prognosis of patients, isochromosome for addition to t(15;17), an incidence higher than that reported in the long arm of the derivative chromosome 17 was probably the literature (from 23 to 39%, mean 28%). [29] [30] [31] [32] However, no associated with poor outcome. All three patients with correlation between the extrachromosomal abnormalities and ider(17q) by cytogenetic and FISH studies died. The chromo-WBC counts was recognized (data not shown). The ratio of L some aberration results in two RAR␣-PML fusion genes as to S form PML-RAR␣ fusion transcript was 1.8 in this study, well as deletion of the whole short (p) arm of chromosome a value similar to that of American (1.6) 33 and Chinese in 17. A tumor suppressor gene p53 was mapped to 17p13 mainland China 34 but lower than that of Latino patients (5.0) 6 band. 43 Loss of normal p53 expression through 17p deletion and higher than that of Italians (1.1). 35, 36 The differences were or point mutation is suggested as playing an important role in probably due to genetic or environmental heterogeneity.
oncogenesis. 44, 45 In chronic myeloid leukemia, the appearIn this study, concurrent full-dose chemotherapy was not ance of isochromosome 17q usually accompanies transformprescribed to patients who presented with or developed leuation of the disease from chronic phase to acute leukemia. 46, 47 kocytosis during ATRA treatment. This gave us a chance to It is an uncommon chromosomal abnormality in de novo AML observe the incidence and outcome of RA syndrome and the at diagnosis but may be more common at late stage of the prognostic implication of leukocytosis in such patients. The disease or in secondary AML. 48 The incidence of ider(17q) in incidence of RA syndrome in the current report was 36%, APL was 1.9% (3/161) and 4.1% (3/73), respectively, in two similar to that in Western series in which concurrent chemolarge series of studies, but its correlation with clinical features therapy was not routinely used. 12, 16, 37 The low frequency of was not clear. 29, 30 Further studies are needed to clarify the this syndrome in the earlier Chinese reports 28, 38 may be due biologic significance and prognostic implication of this to underestimation (Prof ZY Wang, personal communication).
additional chromosomal abnormality. In the series in which concurrent chemotherapy was preTwo fusion signals were found in some leukemic cells from scribed for patients with leukocytosis initially or during inducseven of the 16 patients who had FISH analysis. None of the tion, the incidence of RA syndrome was low. 11, 39, 40 In this normal controls had such extra signals. All three patients with study, it was demonstrated that patients who presented with ider(17q) and one with der(17)t(15;17)add(17)(p11) showed or developed high WBC count after ATRA treatment tended this change but three other patients without additional to develop RA syndrome. Although corticosteroid treatment chromosomal abnormality also did. The same finding had resulted in excellent control of the syndrome, 37, 40 it is sugbeen reported by Schad et al. 49 The PML and RAR␣ probe gested that patients with high white cell counts receive consets each used consisted of overlapping cosmids. It was specucurrent chemotherapy with ATRA for induction to avoid the lated that one or more of the cosmids in each probe set potential mortality or morbidity of RA syndrome. CD13 hybridized across the PML and/or RAR␣ breakpoint and proexpression was found to be highly associated with the develduced an additional signal. An extra small red or green signal opment of the syndrome in one report, 37 but in the current was also noted in some patients. Another possible explanation study, expression of CD13 or other antigens could not predict is that samples containing cells with triploid or tetraploid the occurrence of the syndrome, nor did the isoform of PMLchromosome number would have more than one fusion sig-RAR␣ fusion transcript.
nal. These additional signals did not interfere with the identiRecent studies have shown that the combination of ATRA fication of samples with PML-RAR␣ fusion gene. FISH study and post-remission intensive chemotherapy in APL patients at metaphase cells is needed to clarify the causes of two fusion increased the CR rate and reduced the incidence of relapse signals in a single cell. as compared with chemotherapy alone. 11, 14, 41 However, some CD2, a T cell-associated marker, was detected in four of 26 patients achieving CR after ATRA and scheduled intensive cases; three of them had S form (3/7) and the remaining one chemotherapy still relapse. It is important to determine proghad L form (1/17). This finding was consistent with the prenostic factors for relapse in these patients so that high-risk vious contention that CD2 was associated with S form tranpatients can be selected for more aggressive treatment such script, 7, 8 although a contradictory result was reported in one as BM transplantation. A strong correlation between DFS durstudy. 9 Combined analysis of the data from all these reports ation and initial or peak WBC counts or WBC increment rate showed significant correlation between CD2 expression and after ATRA treatment was demonstrated in this study, especially in the subgroup of patients receiving anthracycline-S form fusion transcript (P Ͻ 0.005, by 2 test) ( Table 2) . APL group. Prolonged follow up confirms that all-trans retinoic acid followed by chemotherapy reduces the risk of relapse in newly diagnosed acute promyelocytic leukemia. Blood 1994; 84: 666-667.
